Who are Ovarian Stimulation with CC+rFSH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DUOSTIM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ovarian-stimulation-with-cc-rfsh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ovarian Stimulation with CC+rFSH — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ovarian Stimulation with CC+rFSH (Ovarian Stimulation with CC+rFSH) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin combination therapy. Area: Reproductive Medicine / Fertility.

marketed Gonadotropin combination therapy FSH receptor (FSHR); estrogen receptor (ER) antagonism Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Ovarian Stimulation with CC+rFSH (Ovarian Stimulation with CC+rFSH) — Fundación Santiago Dexeus Font. CC+rFSH is a combination hormonal therapy that stimulates ovarian follicle development by blocking negative feedback (clomiphene citrate) while directly stimulating follicle growth (recombinant FSH).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ovarian Stimulation with CC+rFSH TARGET	Ovarian Stimulation with CC+rFSH	Fundación Santiago Dexeus Font	marketed	Gonadotropin combination therapy	FSH receptor (FSHR); estrogen receptor (ER) antagonism
DUOSTIM	DUOSTIM	Centre Hospitalier Intercommunal Creteil	phase 3	Gonadotropin combination therapy	FSH receptor and LH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gonadotropin combination therapy class)

Centre Hospitalier Intercommunal Creteil · 1 drug in this class
Fundación Santiago Dexeus Font · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ovarian Stimulation with CC+rFSH — Competitive Intelligence Brief. https://druglandscape.com/ci/ovarian-stimulation-with-cc-rfsh. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab